L-Carnitine Injection

L-Carnitine is a natural substance in the body that is essential for mammalian energy metabolism. Its main function is to promote lipid metabolism. During ischemia and hypoxia, acyl-CoA accumulates, and long-chain acyl-Carnitine also accumulates in the mitochondria, while free Carnitine decreases due to large-scale consumption. Ischemia and hypoxia lead to a decrease in ATP levels, increased permeability of cell membranes and subcellular membranes, and accumulated acyl-CoA can cause changes in membrane structure, membrane phase collapse, and cell death. In addition, during hypoxia, sugar anaerobic glycolysis is the main process, and the accumulation of fatty acids leads to acidosis, ion disorder, and cell autolysis and death. A sufficient amount of free Carnitine can allow accumulated acyl-CoA to enter the mitochondria, reduce its inhibition of adenine nucleotide translocase, and enable oxidative phosphorylation to proceed smoothly. L-Carnitine is the main energy source for muscle cells, especially myocardial cells. Many tissues and organs such as the brain and kidneys also rely mainly on fatty acid oxidation for energy. Carnitine can also increase the activity of NADH cytochrome reductase and cytochrome oxidase, accelerate the production of ATP, and participate in the detoxification of certain drugs. For various tissue ischemia and hypoxia, L-carnitine improves the energy supply of tissues and organs by increasing energy production. Other functions of L-carnitine include: oxidation of medium-chain fatty acids; oxidation of fatty acid peroxidase; buffering the ratio of bound coenzyme A to free coenzyme A; generating energy from ketones, pyruvate, and amino acids (including branched-chain amino acids), removing the toxicity of excessive coenzyme A, and regulating blood ammonia concentration.

The main ingredient of this product is L-carnitine.

This product is a colorless clear liquid.

L-Carnitine deficiency secondary to chronic maintenance hemodialysis in end-stage uremia.

Intravenous injection: At the end of each hemodialysis, dilute 1g of this product with 15ml of normal saline and slowly inject it intravenously for 2 to 3 minutes; or intravenous drip, 50mg/kg; the maximum dose is 0.3g/kg/day.

Nausea, vomiting, diarrhea and transient elevation of alanine aminotransferase may occur occasionally.

It is contraindicated for those who are allergic to this product.

Precautions for children: See Dosage and Administration. Precautions for pregnancy and lactation: Although animal experiments cannot prove the reproductive toxicity of L-carnitine, appropriate and controlled studies have not been conducted in pregnant women. The results of animal experiments may differ from those of humans. Pregnant women should use this drug only when it is clinically necessary. It is not clear whether this drug is excreted through breast milk, because many drugs can be excreted through breast milk. Therefore, whether this drug can be used or discontinued during lactation must weigh the pros and cons to the mother. Precautions for the elderly: No appropriate studies have been conducted on the relationship between age and the effects of L-carnitine in the elderly, but it is not expected that there will be any special problems that limit the use of this drug in the elderly.

Based on the potential clinical significance, patients receiving valproate may require an increase in the dose of L-carnitine.

Protect from light and store tightly closed at room temperature.

5 ml: 1 gram

36 months

Changzhou Lanling Pharmaceutical Co., Ltd.

• Founded in:

  1979-01-01

• Address:

  No. 352, Laodong East Road, Changzhou

• Tax NO.:

  91320400137158984C

• Registered Funds:

  25 million yuan

• Website:

  Log in to view

• Email:

  Log in to view